Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variantBMJ 2021; 372 doi: https://doi.org/10.1136/bmj.n296 (Published 01 February 2021) Cite this as: BMJ 2021;372:n296
- Elisabeth Mahase
- The BMJ
The SARS-CoV-2 vaccine produced by the US biotechnology company Novavax is 95.6% effective against the original variant of SARS-CoV-2 but also provides protection against the newer variants B.1.1.7 (85.6%) and B.1.351 (60%), preliminary data from clinical trials show.
Interim results have been released from a phase III trial carried out in the UK with more than 15 000 participants aged between 18 and 84, including 27% over the age of 65. The trial tested two doses of the vaccine administered three weeks apart and reported 62 symptomatic cases of covid-19, of which 56 were in the placebo group (saline) and six in the vaccine group. Of the 62 cases, only one was severe (in the placebo group), and 32 were with the UK variant.
A phase II trial of the Novavax vaccine is also ongoing in South Africa with 4400 volunteers, in which …